Wilky et al., Axitinib plus pembrolizumab in advanced sarcomas including alveolar soft-part sarcoma, Lancet Oncol 2019

Date: 2019-05-08 Category: publication Language: en
Drive path: immunotherapy_suggestion/10.1016@S1470-20451930153-6.pdf

Links: this document on Google Drive [hosted copy]

Summary: Journal article (Lancet Oncology, 2019) reporting a phase 2 trial of axitinib plus pembrolizumab in advanced sarcomas, cited as supporting literature for an immunotherapy second opinion.

Wilky et al., Axitinib plus pembrolizumab in advanced sarcomas including alveolar soft-part sarcoma, Lancet Oncol 2019